Soluble composite microneedle containing ginger exosome as well as preparation method and application of soluble composite microneedle
By combining ginger exosomes with hyaluronic acid and hydroxypropyl chitosan carrier in microneedles, penetrating the skin to deeply treat acne, solving the problem of difficulty in penetrating the stratum corneum and high cost in traditional techniques, achieving efficient antibacterial Anti-inflammatory effect.
Patent Information
- Application Number
- CN202310609619.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-26
- Publication Date
- 2024-11-26
AI Technical Summary
The prior art is difficult to effectively penetrate the stratum corneum of the skin to deliver drugs to the deep acne skin, and traditional antibacterial and anti-inflammatory ingredients are irritating to the skin or have high production costs.
The soluble complex microneedle containing ginger exosomes is used to penetrate the skin by mixing hyaluronic acid and hydroxypropyl chitosan as carriers, and the antibacterial and anti-inflammatory effects are used to treat acne.
Significantly improves the inflammatory environment of wound oxidation, inhibits the growth of Propionibacter acnes, eliminates free radicals, improves drug delivery accuracy and efficiency, has good biocompatibility and antibacterial and anti-inflammatory effects, and is low in cost.
Smart Images

Figure HDA0004253401900000011 
Figure HDA0004253401900000012 
Figure HDA0004253401900000021
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of skin care products or medicines, and relates to a soluble composite microneedle containing ginger exosomes, and a preparation method and application thereof. Background Art
[0002] Acne is an inflammatory skin disease associated with excessive sebum secretion and abnormal keratinization of the sebaceous gland ducts of the hair follicles. When the skin is in an inflamed state due to the above reasons, bacteria will multiply in the hair follicles, especially Propionibacterium acnes (P.acnes), which will lead to the production of free fatty acids and aggravate the local inflammatory response, and eventually form acne lesions. In addition, the occurrence of acne is closely related to the patient's genetics, diet, work, rest and other factors. Various physiological and exogenous factors may become triggers or regulators, such as androgens, neuroendocrine mediators, drugs and foods with high sugar load. It most often occurs in adolescence. Acne may improve with age. However, in most cases, external intervention is still required to accelerate the regression of acne and completely eliminate acne, thereby minimizing the physical and mental effects on the human body. Common treatments for acne include drug application, chemical peeling, photoelectric therapy, etc. The dense stratum corneum of the skin is the biggest obstacle for drugs to penetrate the skin, limiting the percutaneous penetration of most drugs. Only a small number of small molecule drugs can directly enter the epidermis. Macromolecular drugs, such as proteins, nucleic acids, peptides, etc., can hardly penetrate the stratum corneum due to their own hydrophilicity and large particle size.
[0003] An emerging paradigm for effectively delivering drugs and other bioactive substances to the deep skin is the soluble microneedle patch. It is composed of multiple microneedles assembled on one side of a supporting base. The diameter of the microneedle is usually several hundred microns and the length can reach 1000 microns. The tip is very sharp, which can not only penetrate the stratum corneum to improve the accuracy and therapeutic efficiency of drug delivery, but also has the advantage of being painless. In the soluble microneedle, the delivered biological cargo is mixed with a water-soluble polymer in the form of a gel, and then a dry gel is formed by micromolding to prepare the microneedle patch, thereby making drug-loaded microneedles that can penetrate the surface layer of the skin and dissolve in the skin microenvironment without failure. Many studies have demonstrated the effectiveness of soluble microneedle patches for targeted and reproducible delivery of various drugs, vaccines, viral vectors and proteins.
[0004] Ginger is a perennial herbaceous plant of the Zingiberaceae family, which is widely grown in central, eastern, and southwestern my country. It has an aromatic and spicy taste and is a commonly used spice and traditional Chinese medicine. Studies have shown that ginger and its extracts have multiple biological functions such as detoxification, antiemetic and antidiarrhea, anti-oxidation, anti-aging, anti-inflammatory and bactericidal.
[0005] Soluble anti-inflammatory and antibacterial microneedles are rarely studied as a new type of transdermal therapeutic patch. The application document with application number CN112370478A provides a composition with anti-inflammatory and analgesic effects, a soluble microneedle patch and a preparation method thereof, and its anti-inflammatory and analgesic composition includes capsaicin, methyl salicylate, hemp leaf extract and paeonol, but the capsaicin and methyl salicylate used are highly irritating to the skin and mucous membranes. The application document with application number CN 114010579 A provides a soluble anti-inflammatory repair microneedle and a preparation method thereof, and its anti-inflammatory repair composition includes peptide repair compositions, mesenchymal stem cells and their exosomes, fibronectin, mussel mucin, cell growth factors, calming and anti-inflammatory ingredients, and antioxidant ingredients, but the mesenchymal stem cells and their exosomes used have cumbersome production processes, low yields, and high cost prices. Therefore, providing a microneedle patch with excellent biocompatibility and good antibacterial and anti-inflammatory effects and low cost is of great significance for skin acne repair. Summary of the invention
[0006] In view of the shortcomings of the prior art, the present invention provides a soluble composite microneedle containing ginger exosomes and a preparation method and application thereof. The soluble composite microneedle of the present invention can significantly improve the oxidative inflammatory environment of the wound surface and has a good therapeutic effect on acne vulgaris.
[0007] Solution
[0008] To achieve the above object, the present invention provides the following technical solutions:
[0009] In a first aspect, the present invention provides a soluble composite microneedle containing ginger exosomes, comprising a microneedle body and a substrate; the microneedle body comprises ginger exosomes, hydroxypropyl chitosan and hyaluronic acid.
[0010] Furthermore, the weight ratio of the hyaluronic acid to hydroxypropyl chitosan is 4:(0.5-4), optionally 4:(0.5-2), optionally 4:(1-2), optionally 4:2.
[0011] Furthermore, the molecular weight of the hyaluronic acid is 100,000 to 500,000, and optionally 200,000 to 400,000.
[0012] Furthermore, the mass concentration of the hydroxypropyl chitosan before the microneedle body is dried is 0.5-4%, optionally 0.5-2%, optionally 1-2%.
[0013] Furthermore, the mass concentration of the hyaluronic acid before the microneedle body is dried is 3.5-5%, optionally 4%.
[0014] Furthermore, the concentration of the exosomes before the microneedle body is dried is 1×10 8~1×10 11 / mL, optionally 1×10 9 ~1×10 11 / mL, optionally 1×10 9 ~5×10 10 / mL, optionally 1×10 10 ~5×10 10 / mL, optionally 2×10 10 ~3×10 10 Pieces / mL.
[0015] Furthermore, the microneedle body is a cone, the length of the needle body is 800-900 μm, and the width of the needle body is 300-400 μm.
[0016] Further, the substrate of the microneedle includes hyaluronic acid and hydroxypropyl chitosan;
[0017] Furthermore, in the substrate of the microneedle, the weight ratio of the hyaluronic acid to hydroxypropyl chitosan is 4:(0.5-4), optionally 4:(0.5-2), optionally 4:(1-2), optionally 4:2.
[0018] Furthermore, in the substrate of the microneedle, the molecular weight of the hyaluronic acid is 100,000 to 500,000, and optionally 200,000 to 400,000.
[0019] Optionally, the mass concentration of the hyaluronic acid before the microneedle substrate is dried is 3.5-5%, and optionally 4%.
[0020] Furthermore, the mass concentration of the hydroxypropyl chitosan before the microneedle substrate is dried is 0.5-4%, optionally 0.5-2%, optionally 1-2%, optionally 2%.
[0021] In a second aspect, a method for preparing a soluble composite microneedle is provided, including a method for preparing a microneedle body:
[0022] Hyaluronic acid and hydroxypropyl chitosan are added to the ginger exosome solution, mixed evenly to obtain a premixed solution, which is then injected into the microneedle mold so that the premixed solution fills the entire needle cavity of the microneedle mold.
[0023] Furthermore, in the premixed solution, the weight ratio of the hyaluronic acid to hydroxypropyl chitosan is 4:(0.5-4), optionally 4:(0.5-2), optionally 4:(1-2), optionally 4:2.
[0024] Furthermore, in the premixed solution, the molecular weight of the hyaluronic acid is 100,000 to 500,000, and optionally 200,000 to 400,000.
[0025] Furthermore, in the premix solution, the mass concentration of the hyaluronic acid in the premix solution is 3.5-5%, optionally 4%.
[0026] Further, in the premix solution, the mass concentration of the hydroxypropyl chitosan in the premix solution is 0.5-4%, optionally 0.5-2%, optionally 1-2%, optionally 2%;
[0027] Furthermore, in the premixed solution, the concentration of the exosomes in the premixed solution is 1×10 8 ~1×10 11 / mL, optionally 1×10 9 ~1×10 11 / mL, optionally 1×10 9 ~5×10 10 / mL, optionally 1×10 10 ~5×10 10 / mL, optionally 2×10 10 ~3×10 10 Pieces / mL.
[0028] Furthermore, the premixed solution is centrifuged to fill the entire needle cavity of the microneedle mold with the premixed solution.
[0029] Furthermore, it also includes a method for preparing a microneedle substrate: centrifuging or sedimenting a microneedle mold containing a microneedle body premix to make it sink into the needle cavity, injecting a gel solution containing hyaluronic acid and hydroxypropyl chitosan into the microneedle mold to fill the remaining needle cavity with the gel solution, and drying until the microneedles are automatically demolded, thereby obtaining a detachable microneedle patch.
[0030] Furthermore, in the gel solution, the weight ratio of the hyaluronic acid to hydroxypropyl chitosan is 4:(0.5-4), optionally 4:(0.5-2), optionally 4:(1-2), optionally 4:2.
[0031] Furthermore, in the gel solution, the molecular weight of the hyaluronic acid is 100,000 to 500,000, and optionally 200,000 to 400,000.
[0032] Optionally, in the gel solution, the mass concentration of the hyaluronic acid in the gel solution is 3.5-5%, optionally 4%.
[0033] Furthermore, in the gel solution, the mass concentration of the hydroxypropyl chitosan in the gel solution is 0.5-4%, optionally 0.5-2%, optionally 1-2%, optionally 2%.
[0034] Furthermore, the gel solution is centrifuged to fill the remaining needle cavity with the gel solution.
[0035] Furthermore, the preparation method of ginger exosomes is:
[0036] The washed ginger is added to a PBS solution, the juice is squeezed, and the filtrate is filtered to obtain a filtrate, and large particles and cell debris are removed by low-speed centrifugation to obtain a supernatant, the supernatant is ultracentrifuged to obtain an exosome precipitate, and the PBS solution is resuspended to obtain an exosome solution; optionally, the exosome solution is also filtered and sterilized.
[0037] Optionally, the low-speed centrifugation speed is 800g-6000g, and the centrifugation is 10-55min; Optionally, the low-speed centrifugation includes at least two times: one is 800g-1200g, 5-20min; and the other is 4000-6000g, 20-35min;
[0038] Optionally, the ultracentrifugation is: centrifugation at 100,000-300,000 g for 1-5 h, optionally at 120,000-200,000 g for 1-3 h, optionally at 150,000 g for 2 h.
[0039] In a third aspect, there is provided an application of the soluble composite microneedle described in the first aspect or the soluble composite microneedle prepared by the preparation method described in the second aspect, wherein the application is selected from one or more of the following;
[0040] 1) Preparing skin care products or medicines for improving the oxidative inflammatory environment of wound surfaces;
[0041] 2) Preparing skin care products or medicines for preventing or treating acne;
[0042] 3) Preparation of skin care products or medicines for removing skin free radicals.
[0043] In a fourth aspect, a method for improving the oxidative inflammatory environment of a wound, or preventing acne, or treating acne, or removing skin free radicals is provided, wherein a preventive or therapeutically effective amount of the soluble composite microneedles described in the first aspect, or the soluble composite microneedles prepared by the preparation method described in the second aspect, is administered to a subject in need.
[0044] In the third aspect or the fourth aspect, the method for using the soluble composite microneedle is: press the soluble composite microneedle onto the skin, fix it for 5 minutes to 30 minutes, remove the base, and use it continuously for 7 days to 15 days.
[0045] A feasible method for preparing the soluble composite microneedle of the present invention is:
[0046] (1) Preparation of hyaluronic acid / hydroxypropyl chitosan hydrogel: Weigh a certain amount of hyaluronic acid and hydroxypropyl chitosan and dissolve them in phosphate buffered saline (PBS), stirring and dissolving at room temperature, so that the mass concentration of hyaluronic acid in the solution is 4%, and the mass concentration of hydroxypropyl chitosan in the solution is 1%-2%.
[0047] (2) Isolation and purification of ginger exosomes: Wash the purchased fresh ginger with ultrapure water, wipe it dry, weigh the total weight, cut it into small pieces and use a wall-breaking machine to squeeze out the juice. Add a certain weight of ginger pieces into the wall-breaking machine, and add an equal volume of PBS solution so that the liquid level is higher than the ginger, squeeze the juice for 3 minutes to obtain ginger juice. Filter the squeezed ginger juice with filter yarn and funnel, remove the filter residue, and obtain the filtrate. Pour the filtrate into two bottles and balance them, centrifuge them at 1000g for 15 minutes to remove large particles in the ginger, pour the supernatant into a clean bottle and retain it, and discard the precipitate at the bottom. Continue to balance the supernatant, centrifuge it at 5000g for 30 minutes in a centrifuge to remove the broken cell fragments in the ginger, retain the supernatant, and discard the precipitate at the bottom. Finally, the supernatant was centrifuged at 150,000 g for 2 h to remove macromolecular proteins and soluble impurities, retain the ginger-derived exosomes in the precipitate, and the precipitate was resuspended in PBS solution to 2.2 × 10 10 Particles / mL, thus obtaining crude extracted ginger exosomes.
[0048] (3) Preparation of hyaluronic acid / hydroxypropyl chitosan hydrogel loaded with ginger exosomes: a certain amount of hyaluronic acid and hydroxypropyl chitosan were weighed and added to a 2.2×10 10 The mixture was uniformly mixed in a PBS solution of ginger exosomes with a concentration of 100 Particles / mL at 4°C to obtain a hydrogel exosome solution. The mass concentration of hyaluronic acid in the solution was 4%, and the mass concentration of hydroxypropyl chitosan in the solution was 1%-2%.
[0049] (4) Preparation of soluble composite microneedles loaded with ginger exosomes: Clean the PDMS microneedle mold, air-dry it and set aside. Take 1.00mL of the hyaluronic acid / hydroxypropyl chitosan hydrogel solution loaded with ginger exosomes in step (3) and add it to the mold. Centrifuge at 3000-4000rpm for 5min to ensure that the solution enters the mold needle cavity. Remove the bubbles generated by centrifugation in the mold and add 200μL of the gel solution prepared in step (1). Finally, GDEVs@HA / CS-MNs are dried at room temperature and stored at 4°C before use. The prepared microneedle body is conical, with a length of 800-900μm and a width of 300-400μm.
[0050] The present invention prepares GDEVs@HA / CS-MNs by mixing medium molecular weight hyaluronic acid and hydroxypropyl chitosan loaded with ginger-derived exosomes. Compared with a single material, the use of mixed materials greatly reduces the difficulty of microneedle molding and improves the mechanical properties and penetration efficiency of the microneedles. Further, due to the excellent mechanical properties and the controllable and flexible use of microneedle patches, GDEVs@HA / CS-MNs can be accurately fixed on the acne wound surface, and can penetrate the skin surface to directly deliver ginger exosomes to the acne skin microenvironment, which greatly promotes the absorption of exosomes in the acne site and improves the accuracy and efficiency of drug administration. And GDEVs@HA / CS-MNs can play a multi-faceted synergistic therapeutic effect after acting on the skin. First, as the microneedles dissolve, the ginger-derived exosomes can be slowly released, which inhibits the acne inflammation caused by Propionibacterium acnes through the activation of inflammatory cells, keratinocytes, monocytes and sebocytes and the induction of their secretion of pro-inflammatory cytokines such as IL-6 and TNF-α. At the same time, hyaluronic acid is a good natural free radical scavenger, which can eliminate high concentrations of ROS caused by excessive reproduction of P. acnes and reduce damage to the skin. The antibacterial effect of chitosan itself will also increase the bactericidal effect of the treatment. Therefore, GDEVs@HA / CS-MNs is a potential treatment method that can be anti-inflammatory and bactericidal to improve the local microenvironment of acne, and has good practical application value in the treatment of acne.
[0051] Beneficial effects:
[0052] 1) The present invention studies and confirms for the first time that hyaluronic acid and chitosan mixed soluble microneedles loaded with ginger-derived exosomes (GDEVs@HA / CS-MNs) have the effects of improving the oxidative inflammatory environment of the wound surface, inhibiting the growth of Propionibacterium acnes, clearing high concentrations of free radicals caused by excessive reproduction of Propionibacterium acnes (P.acnes), treating common acne, and improving skin effects.
[0053] 2) The present invention adopts this soluble microneedle as a drug penetration-enhancing method, which not only has the advantages of promoting percutaneous absorption, precise positioning, and being easy to fix on the surface of acne wounds, but also can penetrate the surface of the skin and directly deliver ginger exosomes to the acne skin microenvironment, greatly promoting the absorption of exosomes in the acne site and improving the accuracy and efficiency of drug administration. And the present invention loads ginger exosomes into microneedles for the treatment of acne for the first time. Through a series of studies, it has been proved that GDEVs@HA / CS-MNs not only has good biocompatibility, but also has the functions of improving the oxidative inflammatory environment of the wound surface, inhibiting the growth of Propionibacterium acnes, and removing high concentrations of free radicals caused by excessive reproduction of P.acnes, playing a role in synergistic treatment of common acne, accelerating wound repair, and improving skin effects.
[0054] 3) The microneedles prepared by mixing hyaluronic acid and hydroxypropyl chitosan of the present invention not only have good mechanical properties sufficient to penetrate the stratum corneum of the skin, but also have antibacterial and anti-inflammatory, deep moisturizing effects. The ginger exosomes are loaded in the hydrogel microneedles for the treatment of acne, which can not only penetrate the stratum corneum to improve the accuracy of drug administration and the utilization rate of exosomes, but also have the effects of improving the oxidative inflammatory environment of the wound surface, inhibiting the growth of Propionibacterium acnes, clearing high concentrations of free radicals caused by excessive reproduction of Propionibacterium acnes, treating common acne, and improving skin effects.
[0055] 4) The ginger exosomes used in the present invention not only have high yield and low cost, but also have good anti-inflammatory effect. The present invention provides a microneedle patch with excellent biocompatibility, good antibacterial and anti-inflammatory effects and low cost, which is of great significance for skin acne repair. BRIEF DESCRIPTION OF THE DRAWINGS
[0056] One or more embodiments are exemplarily described by the pictures in the accompanying drawings, and these exemplary descriptions do not constitute limitations on the embodiments. The special word "exemplary" here means "used as an example, embodiment or illustrative". Any embodiment described as "exemplary" here is not necessarily interpreted as being superior or better than other embodiments.
[0057] Figure 1 : Nanoparticle tracking analysis (NTA) of Example 1 of the present invention measured the particle concentration of ginger exosomes obtained after separation and concentration.
[0058] Figure 2 : Typical morphology of ginger exosomes observed by transmission electron microscopy in Example 1 of the present invention.
[0059] Figure 3 : Optical image of the microneedle of Example 5 of the present invention.
[0060] Figure 4 : Scanning electron micrograph of the hyaluronic acid and chitosan mixed soluble microneedle patch loaded with ginger-derived exosomes of Example 5 of the present invention.
[0061] Figure 5 : Scanning electron microscope image of a single microneedle of Example 5 of the present invention.
[0062] Figure 6 : The nanoparticle tracking analysis (NTA) of Test Example 1 of the present invention measured the particle concentration of ginger exosomes before and after the addition of microneedles.
[0063] Figure 7 : Mechanical compression test diagram of the microneedle patch of Test Example 2 of the present invention.
[0064] Figure 8: H&E staining of the microneedle penetrating mouse skin tissue section of Test Example 3 of the present invention.
[0065] Fig. 9 : The cell activity of HaCaT cells acted on by the microneedle patch of Test Example 4 of the present invention for 24 hours.
[0066] Fig.10 : The antibacterial property of the microneedle patch was determined by the OD value counting method of Test Example 5 of the present invention.
[0067] Fig.11 : The effects of different embodiments of Test Example 6 of the present invention on cell IL-6 secretion.
[0068] Fig.12 : The effects of different embodiments of Test Example 6 of the present invention on cellular TNF-α secretion.
[0069] Fig.13 : The hyaluronic acid solutions of different molecular weights in Test Example 7 of the present invention, wherein A is a high molecular weight hyaluronic acid solution with a molecular weight of 1.34 million and a concentration of 2%; B is a low molecular weight hyaluronic acid solution with a molecular weight of 6,000 and a concentration of 40%.
[0070] Fig.14 : Scanning electron micrograph of the soluble microneedle patch prepared from high molecular weight hyaluronic acid of Test Example 7 of the present invention.
[0071] Fig.15 : Scanning electron micrograph of the soluble microneedle patch prepared from low molecular weight hyaluronic acid of Test Example 7 of the present invention. DETAILED DESCRIPTION
[0072] To better illustrate the present invention, various exemplary embodiments of the present invention are now described in detail. This detailed description should not be considered as limiting the present invention but should be understood as a more detailed description of certain aspects, features and embodiments of the present invention.
[0073] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific implementations of the present invention without departing from the scope or spirit of the present invention. The present application description and implementation examples are merely exemplary.
[0074] The terms "include", "comprising", "having", "containing", etc. used in this article are open-ended terms, which mean including but not limited to. Unless otherwise specified, all reagents used below are commercial reagents, and the chemical reagents used are not less than analytical grade.
[0075] In the following examples, HA represents hyaluronic acid, and hyaluronic acid of different molecular weights is purchased from Bloomage Biotechnology Co., Ltd.; CS represents hydroxypropyl chitosan, and hydroxypropyl chitosan is purchased from Shanghai Shifeng Biotechnology Co., Ltd. MNs represents the microneedle patch prepared in this article, and GDEVs represents the ginger exosomes prepared in this article.
[0076] Example 1 Preparation of ginger exosomes
[0077] Wash the purchased fresh ginger with ultrapure water and wipe it dry, weigh the total weight, cut it into small pieces for juice extraction with a wall breaker, add a certain weight of ginger pieces to the wall breaker, and add an appropriate amount of PBS solution so that the liquid level is higher than the ginger, squeeze the juice for 3 minutes, and get ginger juice. Filter the squeezed ginger juice with filter yarn, remove the filter residue, and get the filtrate. Pour the filtrate into two bottles and balance them, centrifuge them at 1000g for 15 minutes, remove the large particles of impurities in the ginger, pour the supernatant into a clean bottle and retain it, and discard the precipitate at the bottom. Continue to balance the supernatant, centrifuge it at 4000g for 30 minutes, remove the broken cell fragments in the ginger, retain the supernatant, and discard the bottom precipitate. Finally, centrifuge it at 110000g for 2 hours in an ultracentrifuge to remove the large molecular proteins and soluble impurities in the supernatant, retain the ginger-derived exosomes in the precipitate, and resuspend the precipitate to 2.2×10 10 The crude ginger exosomes were obtained by filtration through a 0.22 μm filter to obtain a PBS suspension of ginger exosomes.
[0078] Nanoparticle tracking analysis (NTA) was used to measure the particle size of ginger exosomes. Figure 1 ; Figure 1 The results show that the average size of the prepared ginger exosomes is 225.3 nm and the total particle concentration is 2.2×10 10 Pieces / mL.
[0079] The morphology was observed using a transmission electron microscope (TEM). Figure 2 ; Figure 2 Display: Ginger exosomes are mainly round or oval vesicle structures.
[0080] Example 2: Preparation of GDEVs@4% HA-MNs
[0081] (1) Preparation of hyaluronic acid gel: Weigh a certain amount of hyaluronic acid and dissolve it in phosphate buffered saline (PBS), stir and dissolve at room temperature to make the mass concentration of hyaluronic acid in the solution 4%. In this embodiment, hyaluronic acid with a molecular weight of 200,000-400,000 is selected.
[0082] (2) Preparation of hyaluronic acid gel loaded with ginger exosomes: a certain amount of hyaluronic acid was weighed and dissolved in a solution containing a concentration of 2.2×10 10 The ginger exosomes were dissolved in a PBS suspension of 100 g / mL of ginger exosomes at 4°C with stirring, so that the mass concentration of hyaluronic acid in the solution was 4%.
[0083] (3) Preparation of soluble composite microneedles loaded with ginger exosomes: Clean the PDMS microneedle mold, air-dry it, and set aside. Add 1.00 mL of the hyaluronic acid solution loaded with ginger exosomes prepared in step (2) to the mold, centrifuge at 3000-4000 rpm for 5 min to ensure that the solution enters the mold cavity, remove the bubbles generated by centrifugation in the mold, and add 200 μL of the hyaluronic acid solution prepared in step (1) as a substrate. Finally, GDEVs@HA-MNs were dried at room temperature and stored in a 4°C refrigerator before use.
[0084] Example 3: Preparation of GDEVs@4%HA+1%CS-MNs
[0085] (1) Preparation of hyaluronic acid / hydroxypropyl chitosan hydrogel: Weigh a certain amount of hyaluronic acid and hydroxypropyl chitosan and dissolve them in PBS, stirring and dissolving at room temperature, so that the mass concentration of hyaluronic acid in the solution is 4%, and the mass concentration of hydroxypropyl chitosan in the solution is 1%. In this embodiment, hyaluronic acid with a molecular weight of 200,000-400,000 is selected.
[0086] (2) Preparation of hyaluronic acid / hydroxypropyl chitosan hydrogel loaded with ginger exosomes: a certain amount of hyaluronic acid and hydroxypropyl chitosan were weighed and dissolved in a solution containing a concentration of 2.2×10 10 The ginger exosomes were dissolved in a PBS suspension of 100 g / mL ginger exosomes and stirred at 4°C to make the mass concentration of hyaluronic acid in the solution 4% and the mass concentration of hydroxypropyl chitosan in the solution 1%.
[0087] (3) Preparation of soluble composite microneedles loaded with ginger exosomes: Clean the PDMS microneedle mold, air-dry it, and set aside. Add 1.00 mL of the hyaluronic acid / hydroxypropyl chitosan hydrogel solution loaded with ginger exosomes prepared in step (2) into the mold, centrifuge at 3000-4000 rpm for 5 min to ensure that the solution enters the mold cavity, remove the bubbles generated by centrifugation in the mold, and add 200 μL of the hyaluronic acid / hydroxypropyl chitosan hydrogel solution prepared in step (1) as a substrate. Finally, GDEVs@HA+1%CS-MNs were dried at room temperature and stored in a 4°C refrigerator before use.
[0088] Example 4: Preparation of GDEVs@4%HA+1.5%CS-MNs
[0089] (1) Preparation of hyaluronic acid / hydroxypropyl chitosan hydrogel: Weigh a certain amount of hyaluronic acid and hydroxypropyl chitosan and dissolve them in PBS, stirring and dissolving at room temperature, so that the mass concentration of hyaluronic acid in the solution is 4%, and the mass concentration of hydroxypropyl chitosan in the solution is 1.5%. In this embodiment, hyaluronic acid with a molecular weight of 200,000-400,000 is selected.
[0090] (2) Preparation of hyaluronic acid / hydroxypropyl chitosan hydrogel loaded with ginger exosomes: appropriate amounts of hyaluronic acid and hydroxypropyl chitosan were dissolved in a solution containing 2.2×10 10 The ginger exosomes were dissolved in a PBS suspension of 100 g / mL ginger exosomes and stirred at 4°C to make the mass concentration of hyaluronic acid in the solution 4% and the mass concentration of hydroxypropyl chitosan in the solution 1.5%.
[0091] (3) Preparation of soluble composite microneedles loaded with ginger exosomes: Clean the PDMS microneedle mold, air-dry it, and set aside. Add 1.00 mL of the hyaluronic acid / hydroxypropyl chitosan hydrogel solution loaded with ginger exosomes prepared in step (2) into the mold, centrifuge at 3000-4000 rpm for 5 min to ensure that the solution enters the mold cavity, remove the bubbles generated by centrifugation in the mold, and add 200 μL of the hyaluronic acid / hydroxypropyl chitosan hydrogel solution prepared in step (1) as a substrate. Finally, GDEVs@HA+1.5% CS-MNs were dried at room temperature and stored in a 4°C refrigerator before use.
[0092] Example 5: Preparation of GDEVs@4%HA+2%CS-MNs
[0093] (1) Preparation of hyaluronic acid / hydroxypropyl chitosan hydrogel: Weigh a certain amount of hyaluronic acid and hydroxypropyl chitosan and dissolve them in PBS, stirring and dissolving at room temperature, so that the mass concentration of hyaluronic acid in the solution is 4%, and the mass concentration of hydroxypropyl chitosan in the solution is 2%. In this embodiment, hyaluronic acid with a molecular weight of 200,000-400,000 is selected.
[0094] (2) Preparation of hyaluronic acid / hydroxypropyl chitosan hydrogel: appropriate amounts of hyaluronic acid and hydroxypropyl chitosan were dissolved in a 2.2×10 10 The ginger exosomes were dissolved in a PBS suspension of 100 g / mL ginger exosomes at room temperature by stirring, so that the mass concentration of hyaluronic acid in the solution was 4% and the mass concentration of hydroxypropyl chitosan in the solution was 2%.
[0095] (3) Preparation of soluble composite microneedles loaded with ginger exosomes: Clean the PDMS microneedle mold, air-dry it, and set aside. Add 1.00 mL of the hyaluronic acid / hydroxypropyl chitosan hydrogel solution loaded with ginger exosomes prepared in step (2) into the mold, centrifuge at 3000-4000 rpm for 5 min to ensure that the solution enters the mold cavity, remove the bubbles generated by centrifugation in the mold, and add 200 μL of the hyaluronic acid / hydroxypropyl chitosan hydrogel solution prepared in step (1) as a substrate. Finally, GDEVs@HA+2%CS-MNs were dried at room temperature and stored in a 4°C refrigerator before use.
[0096] The morphology of the GDEVs@HA+1%CS-MNs patch was observed using a scanning electron microscope and a smartphone camera. Figure 3-Figure 5 The microneedle patch is in a 15×15 pyramid-shaped array with a square needle base, sharp needle tips, and uniform and regular needle morphology. The height of the obtained microneedle patch is 850μm and the bottom width is about 350μm. In the pyramid structure, the sharpness of the needle remains intact.
[0097] Comparative Example 1:
[0098] The difference from Example 5 is that the molecular weight of hyaluronic acid is different. The hyaluronic acid in this comparative example is a macromolecular hyaluronic acid or its sodium salt of 1.3-1.5 million, specifically 1.34 million hyaluronic acid, and the mass concentration of hyaluronic acid in the solution is 2%. When high molecular weight hyaluronic acid or its sodium salt is used to prepare microneedles, due to its low solubility in water, the viscosity of a 2% solution is generally very high, and it is difficult to fill the solution into the mold cavity by centrifugation, resulting in a very incomplete morphology of the microneedles actually prepared, and a 4% solution has a higher viscosity.
[0099] Comparative Example 2:
[0100] The difference from Example 5 is that the molecular weight and concentration of hyaluronic acid are different. The hyaluronic acid in this comparative example is a small molecule hyaluronic acid or its sodium salt with a molecular weight of less than 10,000 to prepare hydrogel: a certain mass of hyaluronic acid with a molecular weight of 6,000 is weighed and dissolved in phosphate buffered saline (PBS), and stirred and dissolved at room temperature to make the mass concentration of hyaluronic acid in the solution 40%. It is difficult to prepare microneedles when the low molecular weight hyaluronic acid with a molecular weight of less than 10,000 is configured as a 4% solution because of its very high solubility in water. Even if it is configured as a 40% solution, it still has good fluidity and the prepared microneedles have poor molding degree (see Fig.15 ).
[0101] Test Example 1: Particle concentration and particle size analysis of ginger exosomes before and after loading microneedles.
[0102] Nanoparticle tracking analysis (NTA) was used to determine the particle size distribution of fresh ginger exosomes (GDEVs) and GDEVs@MNs of Example 5 after reconstitution with PBS, and the concentration and particle size of ginger exosomes before and after loading with microneedle patches were compared and analyzed.
[0103] The test results are as follows Figure 6 The results showed that the average size of the prepared fresh ginger exosomes was 225.3 nm and the total particle concentration was 2.2×10 10 After ginger exosomes were loaded into microneedles and reconstituted with PBS, the average size of ginger exosomes was 289.1 nm, and the total particle concentration was 1.3×10 10 The size distribution of GDEVs dissolved from GDEVs@MNs was not significantly different from that of fresh GDEVs, indicating that the structure of GDEVs was maintained during the preparation process of GDEVs@MNs.
[0104] Test Example 2: Mechanical property test of microneedles.
[0105] The mechanical properties of the microneedle patches of Example 2, Example 3, Example 4, and Example 5 were tested using an electronic universal testing machine. A flat-headed stainless steel cylindrical probe was used to apply a vertically directed force to the microneedle patch at a constant speed of 0.1 mm / min. The displacement and applied force were measured until the microneedle tip broke.
[0106] The test results are as follows Figure 7 As shown, the results show that the microneedle patches with different hydroxypropyl chitosan incorporation amounts exhibit different load-displacement curves, indicating that with the increase in the hydroxypropyl chitosan incorporation amount, the mechanical strength of the microneedle patch increases, and the pressure that a single needle of the microneedle patch of the present invention can withstand is much greater than 0.058N (the minimum pressure required for a single needle to insert into human skin is 0.058N), so the microneedle of the present invention can withstand the pressure of insertion into the skin.
[0107] Test Example 3: In vitro skin penetration efficiency test of microneedles.
[0108] In order to evaluate the skin implantation ability, mice were anesthetized and the back hair was shaved. Then the microneedle patch of Example 5 was applied to the back of the mouse for 5 minutes and then removed. The skin tissue was cut, fixed with 4% paraformaldehyde, and stained with hematoxylin-eosin. The penetration depth of the skin was tested using a laser confocal microscope.
[0109] The test results are as follows Figure 8As shown, the results show that the microneedle patch of Example 5 can easily penetrate the mouse skin under thumb pressure. Histological studies showed that the penetration depth of MNs was 356.86 μm, indicating that the microneedle patch can easily penetrate the epidermis (50-150 μm thick) and reach the dermis.
[0110] After testing, it was found that the microneedles can dissolve quickly when placed in water. After penetrating the epidermis, the microneedles come into contact with tissue fluid and dissolve, releasing exosomes to achieve the therapeutic purpose.
[0111] Test Example 4: Cell activity test of the microneedle patch on HaCaT cells for 24 hours.
[0112] HaCaT cells were cultured in DMEM medium containing 10% fetal bovine serum and 1% penicillin-streptomycin. 4 The cells were inoculated in a 96-well plate at a density of 10 cells / well. The cells were incubated in a CO2 incubator for 24 hours, and then the microneedle patch was diluted with culture medium to obtain microneedle solutions with microneedle patch concentrations of 12.5μg / ml, 25μg / ml, 50μg / ml, 100μg / ml, and 200μg / ml, respectively. The normal culture medium was used as the control group, and the prepared microneedle culture medium solution was used as the experimental group instead of the culture medium for incubation for 24 hours. After the incubation, 10μL CCK-8 reagent was added to each well and incubated at 37°C for 2 hours. The absorbance of each well was measured at a wavelength of 570nm using an enzyme reader.
[0113] The test results are as follows Fig. 9 As shown by Fig. 9 It can be seen that the presence of the microneedle patches of Examples 2, 3, 4 and 5 does not affect the activity of HaCat cells, which indicates that the use of microneedle patches to improve acne will not cause damage to the skin.
[0114] Test Example 5: Antibacterial performance test of microneedle patch.
[0115] The antibacterial properties of the microneedle patches of Example 2, Example 3, Example 4, and Example 5 were tested using the OD value counting method. Propionibacterium acnes (ATCC 6919) was cultured in thioglycollate medium at 37°C under an anaerobic environment. The microneedle patches of Example 2, Example 3, Example 4, and Example 5 were then diluted with thioglycollate medium to prepare culture solutions with microneedle patch concentrations of 62.5μg / ml, 125μg / ml, 250μg / ml, and 500μg / ml, respectively. The thioglycollate medium was used as a control group. Adjust the ultraviolet absorbance of the bacterial solution at 600nm, and dilute the bacterial solution to OD with the prepared different culture solutions. 600 =0.1 (corresponding to a bacterial concentration of 10 6CFU / ml). The cells were cultured at 37°C in an anaerobic environment for 24 h, and the OD value of the bacterial suspension after the microneedle patch was measured using a UV spectrophotometer. 600 Determination of absorbance value.
[0116] like Fig.10 As shown, the results showed that compared with the blank group, with the increase of hydroxypropyl chitosan, the OD value of the experimental group gradually decreased, indicating that the increase in the amount of hydroxypropyl chitosan added significantly enhanced the antibacterial property of the microneedle patch.
[0117] This indicates that the microneedles of the present invention can play a good antibacterial effect after being pierced into the dermis and dissolved in the tissue fluid, thereby achieving the purpose of antibacterial and acne treatment.
[0118] Test Example 6: Enzyme-linked immunosorbent assay (ELISA) was used to test the anti-inflammatory properties of the microneedle patch.
[0119] Mouse mononuclear macrophage cell line RAW264.7 (cell line from American Type Culture Collection (ATCC)) was cultured in DMEM (HIGH GLUCOSE) medium [containing 10% fetal bovine serum (FBS) and 1% penicillin / streptomycin in a 37°C, 5% CO2 incubator.
[0120] RAW264.7 cells growing in logarithmic phase were cultured at 1×10 5 The cells were seeded in a 6-well plate and placed in an incubator for 24 hours. The culture medium was discarded and LPS and drug treatment were given respectively. The experiment was divided into 6 groups: control group (normal culture without LPS stimulation and drug treatment), LPS stimulation group (1 μg / mL LPS was added), EV@HA-MN group (1 μg / mL LPS and 1 mg / mL microneedle solution of Example 2 were added), EV@HA / 1%CS-MN group (1 μg / mL LPS and 1 mg / mL microneedle solution of Example 3 were added), EV@HA / 1.5%CS-MN group (1 μg / mL LPS and 1 mg / mL microneedle solution of Example 4 were added), EV@HA / 2%CS-MN group (1 μg / mL LPS and 1 mg / mL microneedle solution of Example 5 were added), and placed in an incubator for 24 hours. The above microneedle solution was obtained by diluting the microneedle patch with PBS.
[0121] The cell culture supernatant of each group was collected, and the levels of IL-6 and TNF-α in the culture supernatant were determined using an ELISA kit (purchased from BioLegend). Specifically, 100 μL of capture antibody was applied to a 96-well plate and incubated overnight at 4oC. The 96-well plate was then washed 3 times with a wash buffer (PBS buffer containing 0.05% Tween-20) and blocked with an assay diluent (PBS containing 10% FBS) for 1 h at room temperature. The culture medium was aspirated, and 100 μL of standard or sample was added to each well and allowed to stand for 3 hours. The 96-well plate was then washed again, and 100 μL of detection antibody solution was added to each well and incubated for 2 hours. Accordingly, 100 μL of TMB substrate was added to each well under light-proof conditions. The absorbance was measured at 450 nm using an enzyme reader.
[0122] When macrophages are activated, they release pro-inflammatory factors such as IL-6 and TNF-α, which further activate intracellular inflammatory pathways and induce cellular inflammatory responses. Fig.11 , Fig.12 As shown, under the stimulation of 1 μg / mL LPS, RAW264.7 produced a large amount of IL-6 and TNF-α, which was significantly different from the blank control group. Among them, the IL-6 in the LPS group reached about 2 times that of the control group, and the TNF-α reached about 5 times that of the control group, indicating that the cells had an inflammatory response. All four embodiments can significantly reduce the secretion levels of IL-6 and TNF-α in cells. From a numerical perspective, the inhibitory effect of Example 3, Example 4, and Example 5 on the secretion of inflammatory factors is better than that of Example 2, and the effect of Example 5 is the best.
[0123] This indicates that the microneedles of the present invention can play a good anti-inflammatory effect after being inserted into the dermis and dissolved in the tissue fluid, achieving the purpose of anti-inflammatory and acne treatment.
[0124] Test Example 7: The optimal molecular weight of the hyaluronic acid in the present invention was determined by observing the viscosity of high molecular weight and low molecular weight hyaluronic acid.
[0125] Weigh 20 mg of hyaluronic acid with a molecular weight of 1.34 million and dissolve it in 1 mL of phosphate buffered saline (PBS) and stir at room temperature to dissolve. Fig.13 As shown in A, Fig.13 A shows that the viscosity of 2% hyaluronic acid solution is too high to flow, and it is difficult to fill the solution into the mold cavity by centrifugation. The morphology of the microneedle patch prepared by high molecular weight (1.34 million) hyaluronic acid was observed by scanning electron microscopy. Fig.14 As shown, the morphology of the prepared microneedles is very incomplete. Due to the high viscosity, it is difficult to fill the mold cavity by centrifugation, resulting in incomplete tips in many places.
[0126] Weigh 400 mg of hyaluronic acid with a molecular weight of 0.6000 and dissolve it in 1 mL of phosphate buffered saline (PBS), and stir to dissolve at room temperature. Fig.13 As shown in Figure B, it can be seen that low molecular weight hyaluronic acid with a molecular weight of less than 10,000 is used to prepare microneedles. Due to its very high solubility in water, it is still very fluid when configured as a 40% solution. The morphology of the microneedle patch prepared by low molecular weight hyaluronic acid is observed by scanning electron microscopy. Fig.15 As shown, the prepared microneedle has a hollow structure, the needle body is soft and difficult to penetrate into the skin.
[0127] The inventors of the present invention have found that the use of macromolecular hyaluronic acid or its sodium salt with a molecular weight of 1.3-1.5 million to prepare microneedles can improve the mechanical properties of hyaluronic acid microneedle products. However, when high molecular weight hyaluronic acid or its sodium salt is used to prepare microneedles, due to its low solubility in water, the viscosity of a 2% solution is generally very high, and it is difficult to fill the solution into the mold cavity by centrifugation, resulting in the actual prepared microneedle morphology being very incomplete. When low molecular weight hyaluronic acid with a molecular weight of less than 10,000 is used to prepare microneedles, due to its very high solubility in water, it is configured as a 40% solution and still has good fluidity, and the prepared microneedles are hollow structures, and the needle body is soft and difficult to penetrate into the skin. In order to solve the problem that the low solubility and high viscosity of macromolecular hyaluronic acid or its sodium salt lead to incomplete microneedle morphology, while the microneedle body prepared by small molecular hyaluronic acid is too soft, the inventors used medium molecular weight (200,000-400,000) hyaluronic acid and hydroxypropyl chitosan as the needle body and base material to prepare microneedles. Compared with the microneedles prepared by single medium molecular weight hyaluronic acid, the incorporation of hydroxypropyl chitosan greatly improved the penetration efficiency of the microneedles.
[0128] The microneedles prepared in Examples 3 to 5 of the present invention all have good mechanical properties and can easily penetrate the epidermis. The microneedles that penetrate the epidermis dissolve and release exosomes after contacting the tissue fluid, thereby achieving the purpose of treating acne.
[0129] The above description shows and describes the preferred implementation of the present invention. As mentioned above, it should be understood that the present invention is not limited to the form disclosed herein, and should not be regarded as excluding other implementations, but can be used in various other combinations, modifications and environments, and can be modified within the scope of the invention concept described herein through the above teachings or the technology or knowledge of the relevant field. The changes and modifications made by those skilled in the art do not depart from the spirit and scope of the present invention, and should be within the scope of protection of the claims attached to the present invention.
Claims
1. A soluble composite microneedle containing ginger exosomes, characterized in that: It includes a microneedle body and a substrate; The microneedle body comprises ginger exosomes, hyaluronic acid and hydroxypropyl chitosan.
2. The soluble composite microneedle according to claim 1, characterized in that: In the microneedle body, the weight ratio of hyaluronic acid to hydroxypropyl chitosan is 4:(0.5-4), optionally 4:(0.5-2), optionally 4:(1-2), optionally 4:2; And / or, in the microneedle body, the molecular weight of the hyaluronic acid is 100,000 to 500,000, and optionally 200,000 to 400,000.
3. The soluble composite microneedle according to claim 1 or 2, characterized in that: The mass concentration of the hydroxypropyl chitosan before the microneedle body is dried is 0.5-4%, optionally 0.5-2%, optionally 1-2%; And / or, the mass concentration of the hyaluronic acid before the microneedle body is dried is 3.5-5%, optionally 4%; And / or, the concentration of the exosomes before the microneedle body is dried is 1×10 8 ~1×10 11 / mL, optionally 1×10 9 ~1×10 11 / mL, optionally 1×10 9 ~5×10 10 / mL, optionally 1×10 10 ~5×10 10 / mL, optionally 2×10 10 ~3×10 10 Pieces / mL; And / or, the microneedle body is a cone, the length of the needle body is 800-900 μm, and the width of the needle body is 300-400 μm.
4. The soluble composite microneedle according to any one of claims 1 to 3, characterized in that: The substrate of the microneedle includes hyaluronic acid and hydroxypropyl chitosan; Optionally, in the substrate of the microneedle, the weight ratio of the hyaluronic acid to hydroxypropyl chitosan is 4:(0.5-4), optionally 4:(0.5-2), optionally 4:(1-2), optionally 4:2; Optionally, in the microneedle substrate, the molecular weight of the hyaluronic acid is 100,000 to 500,000, and optionally 200,000 to 400,000. Optionally, the mass concentration of the hyaluronic acid before the microneedle substrate is dried is 3.5-5%, optionally 4%; Optionally, the mass concentration of the hydroxypropyl chitosan before the microneedle substrate is dried is 0.5-4%, optionally 0.5-2%, optionally 1-2%, optionally 2%.
5. A method for preparing a soluble composite microneedle, characterized in that: Including a method for preparing a microneedle body: Hyaluronic acid and hydroxypropyl chitosan are added to the ginger exosome solution, mixed evenly to obtain a premixed solution, which is then injected into the microneedle mold so that the premixed solution fills the entire needle cavity of the microneedle mold.
6. The preparation method according to claim 5, characterized in that: In the premixed solution, the weight ratio of the hyaluronic acid to hydroxypropyl chitosan is 4:(0.5-4), optionally 4:(0.5-2), optionally 4:(1-2), optionally 4:2; Optionally, in the premixed solution, the molecular weight of the hyaluronic acid is 100,000 to 500,000, and optionally 200,000 to 400,000; Optionally, in the premix solution, the mass concentration of the hyaluronic acid in the premix solution is 3.5-5%, optionally 4%; Optionally, in the premix solution, the mass concentration of the hydroxypropyl chitosan in the premix solution is 0.5-4%, optionally 0.5-2%, optionally 1-2%, optionally 2%; and / or, in the premixed solution, the concentration of the exosomes in the premixed solution is 1×10 8 ~1×10 11 / mL, optionally 1×10 9 ~1×10 11 / mL, optionally 1×10 9 ~5×10 10 / mL, optionally 1×10 10 ~5×10 10 / mL, optionally 2×10 10 ~3×10 10 Pieces / mL; And / or, the premix solution is centrifuged to fill the entire needle cavity of the microneedle mold with the premix solution.
7. The preparation method according to claim 5 or 6, characterized in that: Also included is a method for preparing a microneedle substrate: The microneedle mold containing the microneedle premix is centrifuged or sedimented to make it sink into the needle cavity, and a gel solution containing hyaluronic acid and hydroxypropyl chitosan is injected into the microneedle mold to fill the remaining needle cavity with the gel solution, and dried until the microneedles are automatically demoulded to obtain a detachable microneedle patch; Optionally, in the gel solution, the weight ratio of the hyaluronic acid to hydroxypropyl chitosan is 4:(0.5-4), optionally 4:(0.5-2), optionally 4:(1-2), optionally 4:2; Optionally, in the gel solution, the molecular weight of the hyaluronic acid is 100,000 to 500,000, and optionally 200,000 to 400,000; Optionally, the mass concentration of the hyaluronic acid in the gel solution is 3.5-5%, optionally 4%; Optionally, the mass concentration of the hydroxypropyl chitosan in the gel solution is 0.5-4%, optionally 0.5-2%, optionally 1-2%, optionally 2%; And / or, the gel solution is centrifuged to fill the remaining needle cavity with the gel solution.
8. The preparation method according to any one of claims 5 to 7, characterized in that: The preparation method of ginger exosomes is as follows: Add the washed ginger to a PBS solution, squeeze the juice, filter to obtain a filtrate, centrifuge at a low speed to remove large particles and cell debris to obtain a supernatant, ultracentrifuge the supernatant to obtain an exosome precipitate, and resuspend in a PBS solution to obtain an exosome solution; optionally, the exosome solution is also filtered and sterilized; Optionally, the low-speed centrifugation speed is 800g-6000g, and the centrifugation is 10-55min; Optionally, the low-speed centrifugation includes at least two times: one is 800g-1200g, 5-20min; and the other is 4000-6000g, 20-35min; Optionally, the ultracentrifugation is: centrifugation at 100,000-300,000 g for 1-5 h, optionally at 120,000-200,000 g for 1-3 h, optionally at 150,000 g for 2 h.
9. An application of the soluble composite microneedle according to any one of claims 1 to 4, or the soluble composite microneedle prepared by the preparation method according to any one of claims 5 to 8, characterized in that: The application is selected from one or more of the following: 1) Preparing skin care products or medicines for improving the oxidative inflammatory environment of wound surfaces; 2) Preparing skin care products or medicines for preventing or treating acne; 3) Preparation of skin care products or medicines for removing skin free radicals.
10. The use according to claim 9, characterized in that: The method for using the soluble composite microneedle is: press the soluble composite microneedle onto the skin, fix it for 5 minutes to 30 minutes, remove the base, and use it continuously for 7 days to 15 days.
Citation Information
Cited By
Fusion membrane of staphylococcus epidermidis vesicles and turmeric-derived exosome-like vesicles as well as preparation method and application of fusion membrane
CN120919253A
